Literature DB >> 8567982

Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes.

S L Tsai1, M H Chen, C T Yeh, C M Chu, A N Lin, F H Chiou, T H Chang, Y F Liaw.   

Abstract

In vitro studies in patients with hepatitis B virus (HBV) infection have suggested that hepatocytolysis induced by CD8+ cytotoxic T lymphocytes (CTLs) is the most important effector pathway in eliminating infected cells. The recognition is implicated in the endogenously processed HBV antigens in the context of HLA class I molecules presented on the liver cell membrane. However, the naturally occurring HBV peptide antigens have not yet been demonstrated. We report here that a naturally processed peptide antigen P2 was isolated from HLA class I molecules of HBV-infected liver cell membrane. The P2 peptide exhibited the activity of sensitizing target cells for lysis by CD8+ CTLs. The P2 sequence (YVNVNMGLK) purified from liver tissue was in concordance with that encoded by the viral genome for the HBV nucleocapsid antigen or HBcAg 88-96. P2 peptide could also be isolated from the EBV-transformed B cells that were transfected by HBcAg-expressing vector. The P2 epitope, sharing the HLA-A11 binding motifs, was recognized by HLA-A11-restricted CD8+ CTLs. The data provided direct evidence that, in hepatitis B patients, antigenic peptides of HBV were processed by hepatocytes, presented with the class I MHC molecules, and recognized by CD8+ CTLs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8567982      PMCID: PMC507052          DOI: 10.1172/JCI118450

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

Review 1.  Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway.

Authors:  O Rötzschke; K Falk
Journal:  Immunol Today       Date:  1991-12

2.  Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.

Authors:  H W Nijman; J G Houbiers; M P Vierboom; S H van der Burg; J W Drijfhout; J D'Amaro; P Kenemans; C J Melief; W M Kast
Journal:  Eur J Immunol       Date:  1993-06       Impact factor: 5.532

3.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

4.  Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection.

Authors:  V Barnaba; A Franco; A Alberti; C Balsano; R Benvenuto; F Balsano
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

5.  Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen.

Authors:  J H Ou; O Laub; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  The role of beta 2-microglobulin in peptide binding by class I molecules.

Authors:  A Vitiello; T A Potter; L A Sherman
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

7.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.

Authors:  A Bertoletti; A Sette; F V Chisari; A Penna; M Levrero; M De Carli; F Fiaccadori; C Ferrari
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

8.  Precore mutations and core clustering mutations in chronic hepatitis B virus infection.

Authors:  W L Chuang; M Omata; T Ehata; O Yokosuka; Y Ito; F Imazeki; S N Lu; W Y Chang; M Ohto
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

9.  Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines.

Authors:  S Guilhot; P Fowler; G Portillo; R F Margolskee; C Ferrari; A Bertoletti; F V Chisari
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen.

Authors:  A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  26 in total

1.  The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen.

Authors:  T T Yuan; G K Sahu; W E Whitehead; R Greenberg; C Shih
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen.

Authors:  T T Yuan; P C Tai; C Shih
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype.

Authors:  Lenong Li; Weifeng Chen; Marlene Bouvier
Journal:  Immunogenetics       Date:  2005-05-04       Impact factor: 2.846

6.  Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

Authors:  Jing You; Lin Zhuang; Hong-Ying Cheng; Shou-Ming Yan; Lan Yu; Jun-Hua Huang; Bao-Zhang Tang; Meng-Ling Huang; Yong-Liang Ma; Virasakdi Chongsuvivatwong; Hutcha Sriplung; Alan Geater; Yan-Wei Qiao; Rong-Xue Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

7.  High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B.

Authors:  C-L Lin; S-L Tsai; T-H Lee; R-N Chien; S-K Liao; Y-F Liaw
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

8.  Mutations in hepatitis B virus core regions correlate with hepatocellular injury in Chinese patients with chronic hepatitis B.

Authors:  Hiroto Tanaka; Hiroki Ueda; Hiroko Hamagami; Susumu Yukawa; Masakazu Ichinose; Motoshige Miyano; Keiji Mimura; Iwao Nishide; Bo-Xin Zhang; Su-Wen Wang; Shi-Oing Zhou; Bei-Hai Li
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 9.  Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B.

Authors:  Osamu Yokosuka; Makoto Arai
Journal:  Med Mol Morphol       Date:  2006-09       Impact factor: 2.309

10.  Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans.

Authors:  William G H Abbott; Peter Tsai; Euphemia Leung; Alex Trevarton; Malakai Ofanoa; John Hornell; Edward J Gane; Stephen R Munn; Allen G Rodrigo
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.